GL1X · GenesisL1 explorer

Research workbench

Structure of human SENP2 in complex with sumo-1

Analyse Structure of human SENP2 in complex with sumo-1 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
1TGZ
Type
protein
Length
302 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Sentrin-specific protease 2; Ubiquitin-like protein SMT3C
EC
3.4.22.-
UniProt
Q9HC62, P63165
Ligands
SO4
Pockets
4 · best druggability 0.61

Structure

x-ray diffraction · 2 distinct chains · 40% helix, 22% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ASentrin-specific protease 2 (EC 3.4.22.-)protein22447% helix, 17% strandQ9HC62
BUbiquitin-like protein SMT3Cprotein7821% helix, 33% strandP63165

Ligands and binding sites

  • SO4 · Sulfate ion · ion · 5 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12710.610.7930empty
21130.520.8217empty
31500.420.7425empty
4720.370.7717empty

Interfaces

1 interface between chains.

  • A–B · 937 Ų buried · 18 hydrogen bonds · protein-protein

Compared structures

  • 1TGZ · Structure of human Senp2 in complex with SUMO-1 · the same entry in another collection · chain A against A, TM-score 1.00
  • Q9HC62 · AlphaFold monomer V2.0 prediction for sentrin-specific protease 2 (Q9HC62) · a predicted model of the same protein · chain A against A, TM-score 0.99
  • P63165 · AlphaFold monomer V2.0 prediction for small ubiquitin-related modifier 1 (P63165) · a predicted model of the same protein · chain B against A, TM-score 0.93

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.